A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type

Not Applicable

• Conditions: metastatic colorectal cancer

• Registration Number: JPRN-UMIN000005218
• Lead Sponsor: Fukuoka Tumor Research(FUTURE)

Brief Summary

o

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-09
• Study Completion: 2012-12-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with severe complications,(severe cardiovascular disease,severe heart disease,heart failure,liver failure,renal failure or uncontrollable diabetes mellitus) 2)Patients with active infection 3)Patients with severe interstitial pneumonitis or pulmonary fibrosis 4)Patients with active double cancer 5)Patients with paralytic ileus, bowel obstruction 6)Patients with uncontrollable ascites and pleural effusion 7)Patients with diarrhea 8)Patients with the past history of severe allergic reactions 9)Patient with regular use of furucytocin or fenytoin,warfarin 10)psychiatric patients 11)pregnant or nursing patient or with intent to bear baby 12)Patients with the past history of treatment of S-1 and CPT-11 and Panitumumab, Cetuximab 13)Patients with regular use of steroids(oral or intravenous) 14)Patients with brain metastasis 15)Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified